What We're Reading: Page 160
Industry reads hand-picked by our editors
Mar 02, 2021
-
Chemical & Engineering News
The fight against fungi
-
The Wall Street Journal
Covid-19 Vaccines Yield Breakthroughs in Long-Term Fight Against Infectious Disease
-
Evaluate Vantage
Early Morphic data hint at a threat to Entyvio
-
Science
New immunotherapy drugs target two evasive cancer-driving proteins
Mar 01, 2021
Feb 26, 2021
Feb 25, 2021
-
BioCentury
Democratic opposition could sink Woodcock’s chances to be nominated as permanent FDA commissioner
-
STAT
GSK's Covid-19 drug falls short in trial, but may benefit older patients
-
Boston Business Journal
Cellarity, Flagship startup that aims to treat 'any disease,' raises $123M
-
Reuters
Regeneron to stop giving placebo in COVID-19 drug trial after 'clear efficacy'
Feb 24, 2021
Feb 23, 2021
-
NPR
History Repeats Itself: COVID-19 Vaccine Inequities Echo HIV Crisis
-
The New York Times
Researchers Halt Trials of Promising Sickle Cell Treatment
-
The Wall Street Journal
To Make More Covid-19 Vaccines, Rival Drugmakers Team Up
Feb 22, 2021
-
The New York Times
Who Will Be the Next F.D.A. Chief?
-
FiercePharma
AbbVie, Eli Lilly lead Big Pharma's 2020 market cap growth as Merck, Gilead lag
-
NPR
Price Check: Nations Pay Wildly Different Prices For Vaccines
-
Endpoints News
Otonomy's resurrected ear drug is now dead again — and investors aren’t hanging around
Previous
